Giovanni Armenise - Harvard Professor of Neurology
Neurofibromatosis and Schwannomatosis. Semin Neurol. 2018 02; 38(1):73-85.
Permeability of the blood-brain barrier to soluble cytokine receptors. Neuroimmunomodulation. 1995 May-Jun; 2(3):161-5.
Permeability of the blood-brain barrier to soluble cytokine receptors.
Huang V, Bergner AL, Halpin C, Merker VL, Sheridan MR, Widemann BC, Blakeley JO, Plotkin SR
Otology & neurotology : official publication of the American Otological Society, American Neurotology Society [and] European Academy of Otology and Neurotology
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2. Otol Neurotol. 2018 06; 39(5):632-638.
Improvement in Patient-reported Hearing After Treatment With Bevacizumab in People With Neurofibromatosis Type 2.
Plotkin SR, Halpin C, McKenna MJ, Loeffler JS, Batchelor TT, Barker FG
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients. Otol Neurotol. 2010 Sep; 31(7):1135-43.
Erlotinib for progressive vestibular schwannoma in neurofibromatosis 2 patients.
Greer DM, Schaefer PW, Plotkin SR, Hasserjian RP, Steere AC
Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck pain, weakness in the arms, and cranial-nerve palsies. N Engl J Med. 2007 Apr 12; 356(15):1561-70.
Case records of the Massachusetts General Hospital. Case 11-2007. A 59-year-old man with neck pain, weakness in the arms, and cranial-nerve palsies.
Blakeley JO, Evans DG, Adler J, Brackmann D, Chen R, Ferner RE, Hanemann CO, Harris G, Huson SM, Jacob A, Kalamarides M, Karajannis MA, Korf BR, Mautner VF, McClatchey AI, Miao H, Plotkin SR, Slattery W, Stemmer-Rachamimov AO, Welling DB, Wen PY, Widemann B, Hunter-Schaedle K, Giovannini M
American journal of medical genetics. Part A
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2. Am J Med Genet A. 2012 Jan; 158A(1):24-41.
Consensus recommendations for current treatments and accelerating clinical trials for patients with neurofibromatosis type 2.
Merker VL, Esparza S, Smith MJ, Stemmer-Rachamimov A, Plotkin SR
Clinical features of schwannomatosis: a retrospective analysis of 87 patients. Oncologist. 2012; 17(10):1317-22.
Clinical features of schwannomatosis: a retrospective analysis of 87 patients.
Dunn GP, Spiliopoulos K, Plotkin SR, Hornicek FJ, Harmon DC, Delaney TF, Williams Z
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1. J Neurosurg. 2013 Jan; 118(1):142-8.
Role of resection of malignant peripheral nerve sheath tumors in patients with neurofibromatosis type 1.
Brastianos PK, Nayyar N, Rosebrock D, Leshchiner I, Gill CM, Livitz D, Bertalan MS, D'Andrea M, Hoang K, Aquilanti E, Chukwueke UN, Kaneb A, Chi A, Plotkin S, Gerstner ER, Frosch MP, Suva ML, Cahill DP, Getz G, Batchelor TT
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens. NPJ Precis Oncol. 2017; 1(1):33.
Resolving the phylogenetic origin of glioblastoma via multifocal genomic analysis of pre-treatment and treatment-resistant autopsy specimens.
Plotkin SR, Banks WA, Maness LM, Kastin AJ
Differential transport of rat and human interleukin-1alpha across the blood-brain barrier and blood-testis barrier in rats. Brain Res. 2000 Oct 20; 881(1):57-61.
Differential transport of rat and human interleukin-1alpha across the blood-brain barrier and blood-testis barrier in rats.
Allaway R, Angus SP, Beauchamp RL, Blakeley JO, Bott M, Burns SS, Carlstedt A, Chang LS, Chen X, Clapp DW, Desouza PA, Erdin S, Fernandez-Valle C, Guinney J, Gusella JF, Haggarty SJ, Johnson GL, La Rosa S, Morrison H, Petrilli AM, Plotkin SR, Pratap A, Ramesh V, Sciaky N, Stemmer-Rachamimov A, Stuhlmiller TJ, Talkowski ME, Welling DB, Yates CW, Zawistowski JS, Zhao WN
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2. PLoS One. 2018; 13(6):e0197350.
Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2.
Wong HK, Lahdenranta J, Kamoun WS, Chan AW, McClatchey AI, Plotkin SR, Jain RK, di Tomaso E
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors. Cancer Res. 2010 May 01; 70(9):3483-93.
Anti-vascular endothelial growth factor therapies as a novel therapeutic approach to treating neurofibromatosis-related tumors.
Wirth LJ, Plotkin SR, Emerick KS, Cunnane ME, Faquin WC
Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer. N Engl J Med. 2012 Sep 20; 367(12):1136-47.
Case records of the Massachusetts General Hospital. Case 29-2012. A 49-year-old man with pain and cranial-nerve palsies after treatment of oral cancer.
In: Longo D, Chabner B, and Lynch T, editors. Harrison's Handbook of Oncology
Metastatic brain tumors. In: Longo D, Chabner B, and Lynch T, editors. Harrison's Handbook of Oncology. 2007.
Smith MJ, Walker JA, Shen Y, Stemmer-Rachamimov A, Gusella JF, Plotkin SR
Expression of SMARCB1 (INI1) mutations in familial schwannomatosis. Hum Mol Genet. 2012 Dec 15; 21(24):5239-45.
Expression of SMARCB1 (INI1) mutations in familial schwannomatosis.
Batchelor TT, Sorensen AG, di Tomaso E, Zhang WT, Duda DG, Cohen KS, Kozak KR, Cahill DP, Chen PJ, Zhu M, Ancukiewicz M, Mrugala MM, Plotkin S, Drappatz J, Louis DN, Ivy P, Scadden DT, Benner T, Loeffler JS, Wen PY, Jain RK
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients. Cancer Cell. 2007 Jan; 11(1):83-95.
AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.
Brain metastases. Curr Treat Options Neurol. 2008 Jul; 10(4):308-14.
Plotkin SR, Halpin C, Blakeley JO, Slattery WH, Welling DB, Chang SM, Loeffler JS, Harris GJ, Sorensen AG, McKenna MJ, Barker FG
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma. J Neurooncol. 2009 May; 93(1):61-77.
Suggested response criteria for phase II antitumor drug studies for neurofibromatosis type 2 related vestibular schwannoma.
James MF, Han S, Polizzano C, Plotkin SR, Manning BD, Stemmer-Rachamimov AO, Gusella JF, Ramesh V
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth. Mol Cell Biol. 2009 Aug; 29(15):4250-61.
NF2/merlin is a novel negative regulator of mTOR complex 1, and activation of mTORC1 is associated with meningioma and schwannoma growth.
Angus SP, Oblinger JL, Stuhlmiller TJ, DeSouza PA, Beauchamp RL, Witt L, Chen X, Jordan JT, Gilbert TSK, Stemmer-Rachamimov A, Gusella JF, Plotkin SR, Haggarty SJ, Chang LS, Johnson GL, Ramesh V
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma. Neuro Oncol. 2018 08 02; 20(9):1185-1196.
EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
Verma SK, Riccardi VM, Plotkin SR, Weinberg H, Anderson RR, Blakeley JO, Jarnagin K, Lee J
Considerations for development of therapies for cutaneous neurofibroma. Neurology. 2018 07 10; 91(2 Suppl 1):S21-S30.
Considerations for development of therapies for cutaneous neurofibroma.
Ortonne N, Wolkenstein P, Blakeley JO, Korf B, Plotkin SR, Riccardi VM, Miller DC, Huson S, Peltonen J, Rosenberg A, Carroll SL, Verma SK, Mautner V, Upadhyaya M, Stemmer-Rachamimov A
Cutaneous neurofibromas: Current clinical and pathologic issues. Neurology. 2018 07 10; 91(2 Suppl 1):S5-S13.
Cutaneous neurofibromas: Current clinical and pathologic issues.
van Eeghen AM, Pulsifer MB, Merker VL, Neumeyer AM, van Eeghen EE, Thibert RL, Cole AJ, Leigh FA, Plotkin SR, Thiele EA
Developmental medicine and child neurology
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach. Dev Med Child Neurol. 2013 Feb; 55(2):146-153.
Understanding relationships between autism, intelligence, and epilepsy: a cross-disorder approach.
Benign Intracranial Tumors. Neurol Clin. 2018 08; 36(3):501-516.
Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, and Plotkin SR
Determination of Tumor Burden in NF1, NF2, and Schwannomatosis on Whole Body MR Images. Radiology. 2009; 250(3):665-73.
Determination of Tumor Burden in NF1, NF2, and Schwannomatosis on Whole Body MR Images
Boyd C, Smith MJ, Kluwe L, Balogh A, Maccollin M, Plotkin SR
Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis. Clin Genet. 2008 Oct; 74(4):358-66.
Alterations in the SMARCB1 (INI1) tumor suppressor gene in familial schwannomatosis.
di Tomaso E, Snuderl M, Kamoun WS, Duda DG, Auluck PK, Fazlollahi L, Andronesi OC, Frosch MP, Wen PY, Plotkin SR, Hedley-Whyte ET, Sorensen AG, Batchelor TT, Jain RK
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape. Cancer Res. 2011 Jan 01; 71(1):19-28.
Glioblastoma recurrence after cediranib therapy in patients: lack of "rebound" revascularization as mode of escape.
Merker VL, Dai A, Radtke HB, Knight P, Jordan JT, Plotkin SR
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis. BMC Health Serv Res. 2018 Aug 29; 18(1):668.
Increasing access to specialty care for rare diseases: a case study using a foundation sponsored clinic network for patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis.
Jaremko JL, MacMahon PJ, Torriani M, Merker VL, Mautner VF, Plotkin SR, Bredella MA
Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol. 2012 Aug; 41(8):917-23.
Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis.
Terry AR, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR
Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study. Neuro Oncol. 2012 Jun; 14(6):768-76.
Outcomes of hospitalization in pregnant women with CNS neoplasms: a population-based study.
In: Wen PY, Glanz MJ, editors. Neurologic Clinics: Neurologic Complications of Cancer
Neurologic complications of cancer therapy. In: Wen PY, Glanz MJ, editors. Neurologic Clinics: Neurologic Complications of Cancer. 2003; 21(1):279-318.
Neurologic complications of cancer therapy
Whitley R, Arvin A, Prober C, Corey L, Burchett S, Plotkin S, Starr S, Jacobs R, Powell D, Nahmias A
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):450-4.
Predictors of morbidity and mortality in neonates with herpes simplex virus infections. The National Institute of Allergy and Infectious Diseases Collaborative Antiviral Study Group.
David Reardon, Karen Fink, Tom Mikkelsen, Timothy Cloughesy, Alison O'Neill, Scott Plotkin, Michael Glantz, Paula Ravin, Jeffrey Raizer, Keith Rich, David Schiff, William Shapiro, Susan Burdette-Radoux, Edward Dropcho, Sabine Wittemer, Johannes Nippgen, Martin Picard, Louis Nabors
Activity of Cilengitide, an Integrin-Targeting RGD Peptide, Among Adults with Recurrent Glioblastoma Multiforme: Results of a Randomized Phase 2 Study. J Clin Oncol. 2008; 26(34):5610-5617.
Activity of Cilengitide, an Integrin-Targeting RGD Peptide, Among Adults with Recurrent Glioblastoma Multiforme: Results of a Randomized Phase 2 Study
Ruggieri M, Pascual-Castroviejo I, and DiRocco C, editors. Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Sydnromes
Neurofibromatosis type 2 and related disorders. Ruggieri M, Pascual-Castroviejo I, and DiRocco C, editors. Neurocutaneous Disorders: Phakomatoses and Hamartoneoplastic Sydnromes. 2008; 153-180.
Neurofibromatosis type 2 and related disorders
Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier. J Neuroimmunol. 1996 Jun; 67(1):41-7.
Comparison of saturable transport and extracellular pathways in the passage of interleukin-1 alpha across the blood-brain barrier.
The Neurofibromatoses. Part 1: NF1. Rev Neurol Dis. 2009; 6(2):E47-53.
Vranceanu AM, Zale EL, Funes CJ, Macklin EA, McCurley J, Park ER, Jordan JT, Lin A, Plotkin SR
Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial. JMIR Res Protoc. 2018 Oct 23; 7(10):e11008.
Mind-Body Treatment for International English-Speaking Adults With Neurofibromatosis via Live Videoconferencing: Protocol for a Single-Blind Randomized Controlled Trial.
Nunes FP, Merker VL, Jennings D, Caruso PA, di Tomaso E, Muzikansky A, Barker FG, Stemmer-Rachamimov A, Plotkin SR
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients. PLoS One. 2013; 8(3):e59941.
Bevacizumab treatment for meningiomas in NF2: a retrospective analysis of 15 patients.
Brain metastases. Office Practice of Neurology. 2002.
Ly KI, Vakulenko-Lagun B, Emblem KE, Ou Y, Da X, Betensky RA, Kalpathy-Cramer J, Duda DG, Jain RK, Chi AS, Plotkin SR, Batchelor TT, Sorensen G, Rosen BR, Gerstner ER
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2018 11 20; 8(1):17062.
Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Wang DL, Smith KB, Esparza S, Leigh FA, Muzikansky A, Park ER, Plotkin SR
Genetics in medicine : official journal of the American College of Medical Genetics
Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome. Genet Med. 2012 Dec; 14(12):977-82.
Emotional functioning of patients with neurofibromatosis tumor suppressor syndrome.
Plotkin SR, Blakeley JO, Evans DG, Hanemann CO, Hulsebos TJ, Hunter-Schaedle K, Kalpana GV, Korf B, Messiaen L, Papi L, Ratner N, Sherman LS, Smith MJ, Stemmer-Rachamimov AO, Vitte J, Giovannini M
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria. Am J Med Genet A. 2013 Mar; 161A(3):405-16.
Update from the 2011 International Schwannomatosis Workshop: From genetics to diagnostic criteria.
In: Baehring JM and Piepmeier JM, editors. Brain tumors: practical guide to diagnosis and treatment
Increased intracranial pressure and extradural compression syndromes. In: Baehring JM and Piepmeier JM, editors. Brain tumors: practical guide to diagnosis and treatment. 2007; 89:427-446.
Increased intracranial pressure and extradural compression syndromes
Designing clinical trials for cutaneous neurofibromas, an unmet medical need for patients with neurofibromatosis 1
Chen J, Landegger LD, Sun Y, Ren J, Maimon N, Wu L, Ng MR, Chen JW, Zhang N, Zhao Y, Gao X, Fujita T, Roberge S, Huang P, Jain RK, Plotkin SR, Stankovic KM, Xu L
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma. Nat Protoc. 2019 02; 14(2):541-555.
A cerebellopontine angle mouse model for the investigation of tumor biology, hearing, and neurological function in NF2-related vestibular schwannoma.
The neurofibromatoses. Part 2: NF2 and schwannomatosis. Rev Neurol Dis. 2009; 6(3):E81-6.
The neurofibromatoses. Part 2: NF2 and schwannomatosis.
Rosenberg RN, DiMauro S, Paulson H, Ptacek L, Nestler E, editors. The molecular and genetic basis of neurological and psychiatric disease
The Phakomatoses. Rosenberg RN, DiMauro S, Paulson H, Ptacek L, Nestler E, editors. The molecular and genetic basis of neurological and psychiatric disease. 2007.
Ferner RE, Bakker A, Elgersma Y, Evans DGR, Giovannini M, Legius E, Lloyd A, Messiaen LM, Plotkin S, Reilly KM, Schindeler A, Smith MJ, Ullrich NJ, Widemann B, Sherman LS
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis. Am J Med Genet A. 2019 06; 179(6):1098-1106.
From process to progress-2017 International Conference on Neurofibromatosis 1, Neurofibromatosis 2 and Schwannomatosis.
Rauen KA, Alsaegh A, Ben-Shachar S, Berman Y, Blakeley J, Cordeiro I, Elgersma Y, Evans DG, Fisher MJ, Frayling IM, George J, Huson SM, Kerr B, Khire U, Korf B, Legius E, Messiaen L, van Minkelen R, Nampoothiri S, Ngeow J, Parada LF, Phadke S, Pillai A, Plotkin SR, Puri R, Raji A, Ramesh V, Ratner N, Shankar SP, Sharda S, Tambe A, Vikkula M, Widemann BC, Wolkenstein P, Upadhyaya M
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics. Am J Med Genet A. 2019 06; 179(6):1091-1097.
First International Conference on RASopathies and Neurofibromatoses in Asia: Identification and advances of new therapeutics.
Funes CJ, Mace RA, Macklin EA, Plotkin SR, Jordan JT, Vranceanu AM
First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial. J Neurooncol. 2019 Jul; 143(3):505-513.
First report of quality of life in adults with neurofibromatosis 2 who are deafened or have significant hearing loss: results of a live-video randomized control trial.
Professor of Psychology in the Department of Psychiatry
Corresponding Member of the Faculty of Neurology
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI. Sci Rep. 2019 Jun 14; 9(1):8721.
Publisher Correction: Probing tumor microenvironment in patients with newly diagnosed glioblastoma during chemoradiation and adjuvant temozolomide with functional MRI.
Martin A. Samuels Professor of Neurology
William and Elizabeth Sweet Professor of Neurosurgery
Gerstner ER, Emblem KE, Chang K, Vakulenko-Lagun B, Yen YF, Beers AL, Dietrich J, Plotkin SR, Catana C, Hooker JM, Duda DG, Rosen B, Kalpathy-Cramer J, Jain RK, Batchelor T
Clinical cancer research : an official journal of the American Association for Cancer Research
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma. Clin Cancer Res. 2020 01 01; 26(1):206-212.
Bevacizumab Reduces Permeability and Concurrent Temozolomide Delivery in a Subset of Patients with Recurrent Glioblastoma.
Plotkin SR, Duda DG, Muzikansky A, Allen J, Blakeley J, Rosser T, Campian JL, Clapp DW, Fisher MJ, Tonsgard J, Ullrich N, Thomas C, Cutter G, Korf B, Packer R, Karajannis MA
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma. J Clin Oncol. 2019 12 10; 37(35):3446-3454.
Multicenter, Prospective, Phase II and Biomarker Study of High-Dose Bevacizumab as Induction Therapy in Patients With Neurofibromatosis Type 2 and Progressive Vestibular Schwannoma.
Greenberg J, Carter S, Lester E, Funes CJ, Macklin EA, Plotkin S, Vranceanu AM
Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial. J Neurooncol. 2019 Dec; 145(3):561-569.
Cultivating resiliency in patients with neurofibromatosis 2 who are deafened or have severe hearing loss: a live-video randomized control trial.
Lester E, DiStefano S, Mace R, Macklin E, Plotkin S, Vranceanu AM
Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial. Gen Hosp Psychiatry. 2020 Jan - Feb; 62:72-78.
Virtual mind-body treatment for geographically diverse youth with neurofibromatosis: A pilot randomized controlled trial.
Lester EG, Macklin EA, Plotkin S, Vranceanu AM
Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program. J Neurooncol. 2020 Apr; 147(2):451-457.
Improvement in resiliency factors among adolescents with neurofibromatosis who participate in a virtual mind-body group program.
Klesse LJ, Jordan JT, Radtke HB, Rosser T, Schorry E, Ullrich N, Viskochil D, Knight P, Plotkin SR, Yohay K
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities. Oncologist. 2020 07; 25(7):e1109-e1116.
The Use of MEK Inhibitors in Neurofibromatosis Type 1-Associated Tumors and Management of Toxicities.
Liu Y, Jordan JT, Bredella MA, Erdin S, Walker JA, Vangel M, Harris GJ, Plotkin SR, Cai W
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics. Neurology. 2020 06 16; 94(24):e2521-e2531.
Correlation between NF1 genotype and imaging phenotype on whole-body MRI: NF1 radiogenomics.
Rios JJ, Richards BS, Stevenson DA, Oberlander B, Viskochil D, Gross AM, Dombi E, Widemann BC, Plotkin SR, May CJ, Ullrich NJ, Goldstein RY, Jain V, Schorry EK
Are Some Randomized Clinical Trials Impossible? J Pediatr Orthop. 2021 Jan; 41(1):e90-e93.
Are Some Randomized Clinical Trials Impossible?
Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4.
Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma.
Mansouri S, Suppiah S, Mamatjan Y, Paganini I, Liu JC, Karimi S, Patil V, Nassiri F, Singh O, Sundaravadanam Y, Rath P, Sestini R, Gensini F, Agnihotri S, Blakeley J, Ostrow K, Largaespada D, Plotkin SR, Stemmer-Rachamimov A, Ferrer MM, Pugh TJ, Aldape KD, Papi L, Zadeh G
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 01; 141(1):101-116.
Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Merker VL, Plotkin SR, Charns MP, Meterko M, Jordan JT, Elwy AR
Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis. Patient Educ Couns. 2021 04; 104(4):808-814.
Effective provider-patient communication of a rare disease diagnosis: A qualitative study of people diagnosed with schwannomatosis.
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis. Acta Neuropathol. 2021 Jan; 141(1):117.
Correction to: Epigenomic, genomic, and transcriptomic landscape of schwannomatosis.
Beauchamp RL, Erdin S, Witt L, Jordan JT, Plotkin SR, Gusella JF, Ramesh V
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2021 Jan-Jun; 296:100157.
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition.
Familial Nervous System Tumor Syndromes. Continuum (Minneap Minn). 2020 12; 26(6):1523-1552.
Familial Nervous System Tumor Syndromes.
Fisher MJ, Shih CS, Rhodes SD, Armstrong AE, Wolters PL, Dombi E, Zhang C, Angus SP, Johnson GL, Packer RJ, Allen JC, Ullrich NJ, Goldman S, Gutmann DH, Plotkin SR, Rosser T, Robertson KA, Widemann BC, Smith AE, Bessler WK, He Y, Park SJ, Mund JA, Jiang L, Bijangi-Vishehsaraei K, Robinson CT, Cutter GR, Korf BR, Blakeley JO, Clapp DW
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial. Nat Med. 2021 01; 27(1):165-173.
Cabozantinib for neurofibromatosis type 1-related plexiform neurofibromas: a phase 2 trial.
mTOR kinase inhibition disrupts neuregulin 1-ERBB3 autocrine signaling and sensitizes NF2-deficient meningioma cellular models to IGF1R inhibition. J Biol Chem. 2020 Dec 09; 296:100157.
Weiss BD, Wolters PL, Plotkin SR, Widemann BC, Tonsgard JH, Blakeley J, Allen JC, Schorry E, Korf B, Robison NJ, Goldman S, Vinks AA, Emoto C, Fukuda T, Robinson CT, Cutter G, Edwards L, Dombi E, Ratner N, Packer R, Fisher MJ
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas. J Clin Oncol. 2021 03 01; 39(7):797-806.
NF106: A Neurofibromatosis Clinical Trials Consortium Phase II Trial of the MEK Inhibitor Mirdametinib (PD-0325901) in Adolescents and Adults With NF1-Related Plexiform Neurofibromas.
Radtke HB, Klein-Tasman BP, Merker VL, Knight P, Ullrich NJ, Jordan JT, Korf B, Plotkin SR
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research. Orphanet J Rare Dis. 2021 02 01; 16(1):61.
The impact of the COVID-19 pandemic on neurofibromatosis clinical care and research.
Dhaenens BAE, Ferner RE, Bakker A, Nievo M, Evans DG, Wolkenstein P, Potratz C, Plotkin SR, Heimann G, Legius E, Oostenbrink R
European journal of human genetics : EJHG
Identifying challenges in neurofibromatosis: a modified Delphi procedure. Eur J Hum Genet. 2021 11; 29(11):1625-1633.
Identifying challenges in neurofibromatosis: a modified Delphi procedure.
Legius E, Messiaen L, Wolkenstein P, Pancza P, Avery RA, Berman Y, Blakeley J, Babovic-Vuksanovic D, Cunha KS, Ferner R, Fisher MJ, Friedman JM, Gutmann DH, Kehrer-Sawatzki H, Korf BR, Mautner VF, Peltonen S, Rauen KA, Riccardi V, Schorry E, Stemmer-Rachamimov A, Stevenson DA, Tadini G, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, Huson SM, Evans DG, Plotkin SR
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation. Genet Med. 2021 08; 23(8):1506-1513.
Revised diagnostic criteria for neurofibromatosis type 1 and Legius syndrome: an international consensus recommendation.
Kukutla P, Ahmed SG, DuBreuil DM, Abdelnabi A, Cetinbas M, Fulci G, Aldikacti B, Stemmer-Rachamimov A, Plotkin SR, Wainger B, Sadreyev RI, Brenner GJ
Annals of clinical and translational neurology
Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas. Ann Clin Transl Neurol. 2021 07; 8(7):1508-1514.
Transcriptomic signature of painful human neurofibromatosis type 2 schwannomas.
Zhang JW, Chen W, Ly KI, Zhang X, Yan F, Jordan J, Harris G, Plotkin S, Hao P, Cai W
IEEE journal of biomedical and health informatics
DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI. IEEE J Biomed Health Inform. 2022 02; 26(2):786-797.
DINs: Deep Interactive Networks for Neurofibroma Segmentation in Neurofibromatosis Type 1 on Whole-Body MRI.
Karajannis MA, Mauguen A, Maloku E, Xu Q, Dunbar EM, Plotkin SR, Yaffee A, Wang S, Roland JT, Sen C, Placantonakis DG, Golfinos JG, Allen JC, Vitanza NA, Chiriboga LA, Schneider RJ, Deng J, Neubert TA, Goldberg JD, Zagzag D, Giancotti FG, Blakeley JO
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma. Mol Cancer Ther. 2021 09; 20(9):1584-1591.
Phase 0 Clinical Trial of Everolimus in Patients with Vestibular Schwannoma or Meningioma.
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead. Neurology. 2021 Aug 16; 97(7 Supplement 1):S1-S3.
Neurofibromatosis Clinical Trials-REiNS Collaboration 2020 Recommendations: Looking Back and Moving Ahead.
Cannon A, Pichard DC, Wolters PL, Adsit S, Erickson G, Lessing AJ, Li P, Narmore W, Röhl C, Rosser T, Widemann BC, Blakeley JO, Plotkin SR
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S15-S24.
Perspective of Adults With Neurofibromatosis 1 and Cutaneous Neurofibromas: Implications for Clinical Trials.
Merker VL, Lessing AJ, Moss I, Hussey M, Oberlander B, Rose T, Thalheimer R, Wirtanen T, Wolters PL, Gross AM, Plotkin SR
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS. Neurology. 2021 08 17; 97(7 Suppl 1):S4-S14.
Enhancing Neurofibromatosis Clinical Trial Outcome Measures Through Patient Engagement: Lessons From REiNS.
Thalheimer RD, Merker VL, Ly KI, Champlain A, Sawaya J, Askenazi NL, Herr HP, Da JLW, Jordan JT, Muzikansky A, Pearce EM, Sakamoto FH, Blakeley JO, Anderson RR, Plotkin SR
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials. Neurology. 2021 08 17; 97(7 Suppl 1):S32-S41.
Validating Techniques for Measurement of Cutaneous Neurofibromas: Recommendations for Clinical Trials.
Maguiness S, Berman Y, Rubin N, Dodds M, Plotkin SR, Wong C, Moertel C
Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1. Neurology. 2021 08 17; 97(7 Suppl 1):S25-S31.
Measuring the Effect of Cutaneous Neurofibromas on Quality of Life in Neurofibromatosis Type 1.
Akshintala S, Khalil N, Yohay K, Muzikansky A, Allen J, Yaffe A, Gross AM, Fisher MJ, Blakeley JO, Oberlander B, Pudel M, Engelson C, Obletz J, Mitchell C, Widemann BC, Stevenson DA, Plotkin SR
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2. Neurology. 2021 08 17; 97(7 Suppl 1):S99-S110.
Reliability of Handheld Dynamometry to Measure Focal Muscle Weakness in Neurofibromatosis Types 1 and 2.
Ahlawat S, Ly KI, Fayad LM, Fisher MJ, Lessing AJ, Berg DJ, Salamon JM, Mautner VF, Babovic-Vuksanovic D, Dombi E, Harris G, Plotkin SR, Blakeley J
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment. Neurology. 2021 08 17; 97(7 Suppl 1):S111-S119.
Imaging Evaluation of Plexiform Neurofibromas in Neurofibromatosis Type 1: A Survey-Based Assessment.
Chang LS, Oblinger JL, Smith AE, Ferrer M, Angus SP, Hawley E, Petrilli AM, Beauchamp RL, Riecken LB, Erdin S, Poi M, Huang J, Bessler WK, Zhang X, Guha R, Thomas C, Burns SS, Gilbert TSK, Jiang L, Li X, Lu Q, Yuan J, He Y, Dixon SAH, Masters A, Jones DR, Yates CW, Haggarty SJ, La Rosa S, Welling DB, Stemmer-Rachamimov AO, Plotkin SR, Gusella JF, Guinney J, Morrison H, Ramesh V, Fernandez-Valle C, Johnson GL, Blakeley JO, Clapp DW
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK. PLoS One. 2021; 16(7):e0252048.
Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK.
Wu L, Vasilijic S, Sun Y, Chen J, Landegger LD, Zhang Y, Zhou W, Ren J, Early S, Yin Z, Ho WW, Zhang N, Gao X, Lee GY, Datta M, Sagers JE, Brown A, Muzikansky A, Stemmer-Rachamimov A, Zhang L, Plotkin SR, Jain RK, Stankovic KM, Xu L
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models. Sci Transl Med. 2021 07 14; 13(602).
Losartan prevents tumor-induced hearing loss and augments radiation efficacy in NF2 schwannoma rodent models.
Lessing AJ, Cote GM, DeLaney TF, Plotkin SR, Raskin KA, Lessing JN
Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report. Case Rep Oncol. 2021 Sep-Dec; 14(3):1342-1346.
Pseudoprogression of Malignant Peripheral Nerve Sheath Tumor in Patient with Neurofibromatosis Type 1, a Case Report.
Hematology/oncology clinics of North America
Neurofibromatoses. Hematol Oncol Clin North Am. 2022 02; 36(1):253-267.
Lassman AB, Wen PY, van den Bent MJ, Plotkin SR, Walenkamp AME, Green AL, Li K, Walker CJ, Chang H, Tamir S, Henegar L, Shen Y, Alvarez MJ, Califano A, Landesman Y, Kauffman MG, Shacham S, Mau-Sørensen M
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma. Clin Cancer Res. 2022 02 01; 28(3):452-460.
A Phase II Study of the Efficacy and Safety of Oral Selinexor in Recurrent Glioblastoma.
Gonzalez Castro LN, Forst DA, Plotkin SR, Lee EQ
A practical guide to neuro-oncology fellowship. J Neurooncol. 2022 Jan; 156(1):73-79.
A practical guide to neuro-oncology fellowship.
Merker VL, Knight P, Radtke HB, Yohay K, Ullrich NJ, Plotkin SR, Jordan JT
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists. Orphanet J Rare Dis. 2022 02 10; 17(1):44.
Awareness and agreement with neurofibromatosis care guidelines among U.S. neurofibromatosis specialists.
Frigault MJ, Dietrich J, Gallagher K, Roschewski M, Jordan JT, Forst D, Plotkin SR, Cook D, Casey KS, Lindell KA, Depinho GD, Katsis K, Elder EL, Leick MB, Choi B, Horick N, Preffer F, Saylor M, McAfee S, O'Donnell PV, Spitzer TR, Dey B, DeFilipp Z, El-Jawahri A, Batchelor TT, Maus MV, Chen YB
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial. Blood. 2022 04 14; 139(15):2306-2315.
Safety and efficacy of tisagenlecleucel in primary CNS lymphoma: a phase 1/2 clinical trial.
Saraf A, Pike LRG, Franck KH, Horick NK, Yeap BY, Fullerton BC, Wang IS, Abazeed ME, McKenna MJ, Mehan WA, Plotkin SR, Loeffler JS, Shih HA
Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial. Neurosurgery. 2022 05 01; 90(5):506-514.
Fractionated Proton Radiation Therapy and Hearing Preservation for Vestibular Schwannoma: Preliminary Analysis of a Prospective Phase 2 Clinical Trial.
Irwin KE, Ko N, Walsh EP, Decker V, Arrillaga-Romany I, Plotkin SR, Franas J, Gorton E, Moy B
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist. 2022 07 05; 27(7):518-524.
Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care.
Merker VL, Slobogean B, Jordan JT, Langmead S, Meterko M, Charns MP, Elwy AR, Blakeley JO, Plotkin SR
Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis. Am J Med Genet A. 2022 09; 188(9):2672-2683.
Understanding barriers to diagnosis in a rare, genetic disease: Delays and errors in diagnosing schwannomatosis.
Plotkin SR, Messiaen L, Legius E, Pancza P, Avery RA, Blakeley JO, Babovic-Vuksanovic D, Ferner R, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Hanemann CO, Kalamarides M, Kehrer-Sawatzki H, Korf BR, Mautner VF, MacCollin M, Papi L, Rauen KA, Riccardi V, Schorry E, Smith MJ, Stemmer-Rachamimov A, Stevenson DA, Ullrich NJ, Viskochil D, Wimmer K, Yohay K, Huson SM, Wolkenstein P, Evans DG
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation. Genet Med. 2022 09; 24(9):1967-1977.
Updated diagnostic criteria and nomenclature for neurofibromatosis type 2 and schwannomatosis: An international consensus recommendation.
Burns R, Niendorf K, Steinberg K, Mueller A, Ly I, Jordan JT, Plotkin SR, Hicks SR
Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis. Am J Med Genet A. 2022 08; 188(8):2413-2420.
Genetic testing to gain diagnostic clarity in neurofibromatosis type 2 and schwannomatosis.
American journal of obstetrics and gynecology
Neurofibromatosis type 1 and pregnancy complications: a population-based study. Am J Obstet Gynecol. 2013 Jul; 209(1):46.e1-8.
Neurofibromatosis type 1 and pregnancy complications: a population-based study.
Da JLW, Merker VL, Jordan JT, Ly KI, Muzikansky A, Parsons M, Wolters PL, Xu L, Styren S, Brown MT, Plotkin SR
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain. Contemp Clin Trials. 2022 10; 121:106900.
Design of a randomized, placebo-controlled, phase 2 study evaluating the safety and efficacy of tanezumab for treatment of schwannomatosis-related pain.
Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Haidar EA, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, Breakefield XO
Molecular therapy. Methods & clinical development
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2022 Sep 08; 26:169-180.
Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.
Ly KI, Merker VL, Cai W, Bredella MA, Muzikansky A, Thalheimer RD, Da JL, Orr CC, Herr HP, Morris ME, Chang CY, Harris GJ, Plotkin SR, Jordan JT
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI. Neurology. 2023 02 14; 100(7):e661-e670.
Ten-Year Follow-up of Internal Neurofibroma Growth Behavior in Adult Patients With Neurofibromatosis Type 1 Using Whole-Body MRI.
Banerjee J, Friedman JM, Klesse LJ, Yohay KH, Jordan JT, Plotkin SR, Allaway RJ, Blakeley JO
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis. Genet Med. 2023 02; 25(2):100324.
COVID-19 in people with neurofibromatosis 1, neurofibromatosis 2, or schwannomatosis.
Gonczol E, Ianacone J, Ho WZ, Starr S, Meignier B, Plotkin S
Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers. Vaccine. 1990 Apr; 8(2):130-6.
Isolated gA/gB glycoprotein complex of human cytomegalovirus envelope induces humoral and cellular immune-responses in human volunteers.
Yin Z, Wu L, Zhang Y, Sun Y, Chen JW, Subudhi S, Ho W, Lee GY, Wang A, Gao X, Ren J, Zhu C, Zhang N, Ferraro GB, Muzikansky A, Zhang L, Stemmer-Rachamimov A, Mao J, Plotkin SR, Xu L
bioRxiv : the preprint server for biology
Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain. bioRxiv. 2023 Feb 06.
Co-Targeting IL-6 and EGFR signaling for the treatment of schwannomatosis and associated pain.
Bhattacharyya S, Oblinger JL, Beauchamp RL, Yin Z, Erdin S, Koundinya P, Ware AD, Ferrer M, Jordan JT, Plotkin SR, Xu L, Chang LS, Ramesh V
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma. Neuro Oncol. 2023 09 05; 25(9):1617-1630.
Proteasomal pathway inhibition as a potential therapy for NF2-associated meningioma and schwannoma.
Rando RF, Srinivasan A, Feingold J, Gonczol E, Plotkin S
Characterization of multiple molecular interactions between human cytomegalovirus (HCMV) and human immunodeficiency virus type 1 (HIV-1). Virology. 1990 May; 176(1):87-97.
Characterization of multiple molecular interactions between human cytomegalovirus (HCMV) and human immunodeficiency virus type 1 (HIV-1).
Cannon A, Sarin KY, Petersen AK, Pichard DC, Wolters PL, Erickson G, Lessing AJ, Li P, Röhl C, Rosser T, Widemann BC, Blakeley JO, Plotkin SR
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials. Clin Trials. 2024 02; 21(1):67-72.
Perspectives of adolescents with neurofibromatosis 1 and cutaneous neurofibromas: Implications for clinical trials.
Jordan JT, Orr CC, Thalheimer RD, Cambillo JV, Beauchamp RL, Shaikh G, Muzikansky A, Stemmer-Rachamimov A, Giovannini M, Kalamarides M, Barker FG, Ramesh V, Plotkin SR
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad041.
Prospective phase II trial of the dual mTORC1/2 inhibitor vistusertib for progressive or symptomatic meningiomas in persons with neurofibromatosis 2.
Vranceanu AM, Manglani HR, Choukas NR, Kanaya MR, Lester E, Zale EL, Plotkin SR, Jordan J, Macklin E, Bakhshaie J
Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial. JAMA Netw Open. 2023 06 01; 6(6):e2320599.
Effect of Mind-Body Skills Training on Quality of Life for Geographically Diverse Adults With Neurofibromatosis: A Fully Remote Randomized Clinical Trial.
Douwes JPJ, Koetsier KS, van Dam VS, Plotkin SR, Barker FG, Welling DB, Jansen JC, Hensen EF, Shih HA
Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series. Curr Oncol. 2023 03 20; 30(3):3473-3483.
Proton Radiotherapy for Vestibular Schwannomas in Patients with NF2-Related Schwannomatosis: A Case Series.
Journal of the American Podiatric Medical Association
Clinical comparison of preinjection anesthetics. J Am Podiatr Med Assoc. 1998 Feb; 88(2):73-9.
Clinical comparison of preinjection anesthetics.
Karschnia P, Arrillaga-Romany IC, Eichler A, Forst DA, Gerstner E, Jordan JT, Ly I, Plotkin SR, Wang N, Martinez-Lage M, Winter SF, Tonn JC, Rejeski K, von Baumgarten L, Cahill DP, Nahed BV, Shankar GM, Abramson JS, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Takvorian RW, Chen YB, Frigault MJ, Dietrich J
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells. Neuro Oncol. 2023 12 08; 25(12):2239-2249.
Neurotoxicity and management of primary and secondary central nervous system lymphoma after adoptive immunotherapy with CD19-directed chimeric antigen receptor T-cells.
Plotkin SR, Allen J, Dhall G, Campian JL, Clapp DW, Fisher MJ, Jain RK, Tonsgard J, Ullrich NJ, Thomas C, Edwards LJ, Korf B, Packer R, Karajannis MA, Blakeley JO
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma. Neuro Oncol. 2023 08 03; 25(8):1498-1506.
Multicenter, prospective, phase II study of maintenance bevacizumab for children and adults with NF2-related schwannomatosis and progressive vestibular schwannoma.
Gross AM, Plotkin SR, Watts NB, Fisher MJ, Klesse LJ, Lessing AJ, McManus ML, Larson AN, Oberlander B, Rios JJ, Sarnoff H, Simpson BN, Ullrich NJ, Stevenson DA
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1. Clin Trials. 2024 02; 21(1):29-39.
Potential endpoints for assessment of bone health in persons with neurofibromatosis type 1.
Karschnia P, Kurz SC, Brastianos PK, Winter SF, Gordon A, Jones S, Pisapia M, Nayyar N, Tonn JC, Batchelor TT, Plotkin SR, Dietrich J
Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens. Neurology. 2023 10 24; 101(17):e1741-e1746.
Association of MTHFR Polymorphisms With Leukoencephalopathy Risk in Patients With Primary CNS Lymphoma Treated With Methotrexate-Based Regimens.
Merker VL, Gross AM, Widemann BC, Plotkin SR
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration. Clin Trials. 2024 02; 21(1):3-5.
Advancing neurofibromatosis and schwannomatosis clinical trial design: Consensus recommendations from the Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNS) International Collaboration.
Sarin KY, Kincaid J, Sell B, Shahryari J, Duncton MAJ, Morefield E, Sun W, Prieto K, Chavez-Chiang O, de Moran Segura C, Nguyen J, Bronson RT, Plotkin SR, Kochendoerfer GG, Fenn P, Wootton MA, Powala C, de Souza MP, Tsai KY
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma. Sci Transl Med. 2023 10 11; 15(717):eade1844.
Development of a MEK inhibitor, NFX-179, as a chemoprevention agent for squamous cell carcinoma.
Fertitta L, Bergqvist C, Sarin KY, Plotkin SR, Moertel C, Petersen AK, Cannon A, Berman Y, Pichard DC, Röhl C, Lessing A, Brizion B, Peiffer B, Ravaud P, Tran VT, Armand ML, Moryousef S, Ferkal S, Jannic A, Ezzedine K, Wolkenstein P
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials. Br J Dermatol. 2024 01 23; 190(2):216-225.
A core outcome domain set to assess cutaneous neurofibromas related to neurofibromatosis type 1 in clinical trials.
Staedtke V, Anstett K, Bedwell D, Giovannini M, Keeling K, Kesterson R, Kim Y, Korf B, Leier A, McManus ML, Sarnoff H, Vitte J, Walker JA, Plotkin SR, Wallis D
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials. Clin Trials. 2024 02; 21(1):51-66.
Gene-targeted therapy for neurofibromatosis and schwannomatosis: The path to clinical trials.
Richey P, Funk M, Sakamoto F, Plotkin S, Ly I, Jordan J, Muzikansky A, Roberts J, Farinelli W, Levin Y, Garibyan L, Blakeley JO, Anderson RR
Journal of the American Academy of Dermatology
Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods. J Am Acad Dermatol. 2024 04; 90(4):767-774.
Noninvasive treatment of cutaneous neurofibromas (cNFs): Results of a randomized prospective, direct comparison of four methods.
Ritvo ER, Yuwiler A, Geller E, Kales A, Rashkis S, Schicor A, Plotkin S, Axelrod R, Howard C
Journal of autism and childhood schizophrenia
Effects of L-dopa in autism. J Autism Child Schizophr. 1971 Apr-Jun; 1(2):190-205.
Bhattacharyya S, Oblinger JL, Beauchamp RL, Kosa L, Robert F, Plotkin SR, Chang LS, Ramesh V
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae024.
Preclinical evaluation of the third-generation, bi-steric mechanistic target of rapamycin complex 1-selective inhibitor RMC-6272 in NF2-deficient models.
Stemmer-Rachamimov AO, Kozanno L, Plotkin SR, Jordan JT, Rd Rizzo JF
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1). Acta Neuropathol. 2024 04 12; 147(1):71.
Histologic correlates of "Choroidal abnormalities" in Neurofibromatosis type 1 (NF1).
Neurofibromatosis and Schwannomatosis Genes Variant Curation Expert Panel (VCEP)
Sarin KY, Bradshaw M, O'Mara C, Shahryari J, Kincaid J, Kempers S, Tu JH, Dhawan S, DuBois J, Wilson D, Horwath P, de Souza MP, Powala C, Kochendoerfer GG, Plotkin SR, Webster GF, Le LQ
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1. Sci Adv. 2024 05 03; 10(18):eadk4946.
Effect of NFX-179 MEK inhibitor on cutaneous neurofibromas in persons with neurofibromatosis type 1.
Prabhakar S, Beauchamp RL, Cheah PS, Yoshinaga A, Abou Haidar E, Lule S, Mani G, Maalouf K, Stemmer-Rachamimov A, Jung DH, Welling DB, Giovannini M, Plotkin SR, Maguire CA, Ramesh V, Breakefield XO
Erratum: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2. Mol Ther Methods Clin Dev. 2024 Jun 13; 32(2):101262.
Erratum: Gene replacement therapy in a schwannoma mouse model of neurofibromatosis type 2.
Hsieh AL, Bi WL, Ramesh V, Brastianos PK, Plotkin SR
Evolving concepts in meningioma management in the era of genomics. Cancer. 2024 Aug 01; 130(15):2586-2600.
Evolving concepts in meningioma management in the era of genomics.
Lu S, Yin Z, Chen J, Wu L, Sun Y, Gao X, Huang P, Jordan JT, Plotkin SR, Xu L
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis. Cancers (Basel). 2024 May 22; 16(11).
Integrating Ataxia Evaluation into Tumor-Induced Hearing Loss Model to Comprehensively Study NF2-Related Schwannomatosis.
Plotkin SR, Yohay KH, Nghiemphu PL, Dinh CT, Babovic-Vuksanovic D, Merker VL, Bakker A, Fell G, Trippa L, Blakeley JO
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors. N Engl J Med. 2024 06 27; 390(24):2284-2294.
Brigatinib in NF2-Related Schwannomatosis with Progressive Tumors.
Dhaenens BAE, Heimann G, Bakker A, Nievo M, Ferner RE, Evans DG, Wolkenstein P, Leubner J, Potratz C, Carton C, Iloeje U, Kirk G, Blakeley JO, Plotkin S, Fisher MJ, Kim A, Driever PH, Azizi AA, Widemann BC, Gross A, Parke T, Legius E, Oostenbrink R
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases. Neurooncol Pract. 2024 Aug; 11(4):395-403.
Platform trial design for neurofibromatosis type 1, NF2-related schwannomatosis and non-NF2-related schwannomatosis: A potential model for rare diseases.
Walter Augustus Lecompte Distinguished Professor of Otology and Laryngology
Stemmer-Rachamimov AO, Kozanno L, Plotkin SR, Jordan JT, Rizzo JF
Reply to L. Lucchino et al. on commentary on "Histologic correlates of "Choroidal Abnormalities" in Neurofibromatosis type 1". Acta Neuropathol. 2024 08 16; 148(1):23.
Reply to L. Lucchino et al. on commentary on "Histologic correlates of "Choroidal Abnormalities" in Neurofibromatosis type 1".
Lu-Emerson C, Snuderl M, Kirkpatrick ND, Goveia J, Davidson C, Huang Y, Riedemann L, Taylor J, Ivy P, Duda DG, Ancukiewicz M, Plotkin SR, Chi AS, Gerstner ER, Eichler AF, Dietrich J, Stemmer-Rachamimov AO, Batchelor TT, Jain RK
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma. Neuro Oncol. 2013 Aug; 15(8):1079-87.
Increase in tumor-associated macrophages after antiangiogenic therapy is associated with poor survival among patients with recurrent glioblastoma.
Cadoz M, Strady A, Meignier B, Taylor J, Tartaglia J, Paoletti E, Plotkin S
Immunisation with canarypox virus expressing rabies glycoprotein. Lancet. 1992 Jun 13; 339(8807):1429-32.
Immunisation with canarypox virus expressing rabies glycoprotein.
Fries LF, Tartaglia J, Taylor J, Kauffman EK, Meignier B, Paoletti E, Plotkin S
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system. Vaccine. 1996 Apr; 14(5):428-34.
Human safety and immunogenicity of a canarypox-rabies glycoprotein recombinant vaccine: an alternative poxvirus vector system.
Vranceanu AM, Merker VL, Park E, Plotkin SR
Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature. J Neurooncol. 2013 Sep; 114(3):257-62.
Quality of life among adult patients with neurofibromatosis 1, neurofibromatosis 2 and schwannomatosis: a systematic review of the literature.
Norden AD, Lesser GJ, Drappatz J, Ligon KL, Hammond SN, Lee EQ, Reardon DR, Fadul CE, Plotkin SR, Batchelor TT, Zhu JJ, Beroukhim R, Muzikansky A, Doherty L, Lafrankie D, Smith K, Tafoya V, Lis R, Stack EC, Rosenfeld MR, Wen PY
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma. Neuro Oncol. 2013 Jul; 15(7):930-5.
Phase 2 study of dose-intense temozolomide in recurrent glioblastoma.
Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib. Neuro Oncol. 2024 Nov 04; 26(11):1949-1950.
Expanding therapeutic options for people with NF2-related schwannomatosis: Encouraging results with brigatinib.
Mendez JS, Cohen AL, Eckenstein M, Jensen RL, Burt LM, Salzman KL, Chamberlain M, Hsu HH, Hutchinson M, Iwamoto F, Ligon KL, Mrugala MM, Pelayo M, Plotkin SR, Puduvalli VK, Raizer J, Reardon DA, Sterba M, Walbert T, West BL, Wong ET, Zhang C, Colman H
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma. Neurooncol Adv. 2024 Jan-Dec; 6(1):vdae202.
Phase 1b/2 study of orally administered pexidartinib in combination with radiation therapy and temozolomide in patients with newly diagnosed glioblastoma.
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen BR, Loeffler JS, Wen PY, Sorensen AG, Jain RK
Proceedings of the National Academy of Sciences of the United States of America
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation. Proc Natl Acad Sci U S A. 2013 Nov 19; 110(47):19059-64.
Improved tumor oxygenation and survival in glioblastoma patients who show increased blood perfusion after cediranib and chemoradiation.
Plotkin SR, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Widemann BC
Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology. 2013 Nov 19; 81(21 Suppl 1):S1-5.
Achieving consensus for clinical trials: the REiNS International Collaboration.
Plotkin SR, Ardern-Holmes SL, Barker FG, Blakeley JO, Evans DG, Ferner RE, Hadlock TA, Halpin C
Hearing and facial function outcomes for neurofibromatosis 2 clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S25-32.
Hearing and facial function outcomes for neurofibromatosis 2 clinical trials.
Dombi E, Ardern-Holmes SL, Babovic-Vuksanovic D, Barker FG, Connor S, Evans DG, Fisher MJ, Goutagny S, Harris GJ, Jaramillo D, Karajannis MA, Korf BR, Mautner V, Plotkin SR, Poussaint TY, Robertson K, Shih CS, Widemann BC
Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology. 2013 Nov 19; 81(21 Suppl 1):S33-40.
Recommendations for imaging tumor response in neurofibromatosis clinical trials.
Widemann BC, Blakeley JO, Dombi E, Fisher MJ, Hanemann CO, Walsh KS, Wolters PL, Plotkin SR
Conclusions and future directions for the REiNS International Collaboration. Neurology. 2013 Nov 19; 81(21 Suppl 1):S41-4.
Conclusions and future directions for the REiNS International Collaboration.
Hayward JC, Gillespie SM, Kaplan KM, Packer R, Pallansch M, Plotkin S, Schonberger LB
The Pediatric infectious disease journal
Outbreak of poliomyelitis-like paralysis associated with enterovirus 71. Pediatr Infect Dis J. 1989 Sep; 8(9):611-6.
Outbreak of poliomyelitis-like paralysis associated with enterovirus 71.
Dombi E, Gross AM, Widemann BC, Weiss BD, Plotkin SR, Ahlawat S
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas. J Clin Oncol. 2025 May 20; 43(15):1843-1844.
Challenges in Assessing Response in Clinical Trials for Neurofibromatosis Type 1 Plexiform Neurofibromas.
Gonzalez Castro LN, Gavish A, Bussema L, Mount CW, Neftel C, Nomura M, Chiocca EA, Bi WL, Arnaout O, Barker FG, Brown JM, Jordan JT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR, Tirosh I, Suvà ML
A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations. Genome Med. 2025 Apr 11; 17(1):37.
A single-cell atlas of Schwannoma across genetic backgrounds and anatomic locations.
Merker VL, Ma Y, Chibnik LB, Radtke HB, Kelts K, Yohay K, Ullrich NJ, Plotkin SR, Jordan JT
Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national survey. Orphanet J Rare Dis. 2025 Apr 16; 20(1):185.
Self-reported access to specialty clinics and receipt of health surveillance among U.S. patients with neurofibromatosis 1: a national survey.
Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness. Psychooncology. 2013 Dec; 22(12):2711-9.
Appearance concerns among women with neurofibromatosis: examining sexual/bodily and social self-consciousness.
Plotkin SR, Merker VL, Muzikansky A, Barker FG, Slattery W
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients. Otol Neurotol. 2014 Jan; 35(1):e50-6.
Natural history of vestibular schwannoma growth and hearing decline in newly diagnosed neurofibromatosis type 2 patients.
Nakhate V, Ly I, Muzikansky A, Rapalino O, Allen JC, Blakeley JO, Campian JL, Clapp DW, Dhall G, Jain RK, Karajannis MA, Packer RJ, Tonsgard J, Ullrich NJ, Korf BR, Fisher MJ, Plotkin SR
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104. J Neurooncol. 2025 Jul; 173(3):751-757.
Effect of bevacizumab on non-target intracranial meningiomas and non-vestibular schwannomas in NF2-related schwannomatosis: NF104.
Ramapriyan R, Barker FG, Richardson LG, Sun J, Vandecandelaere G, Shim JM, De Vlaminck G, Gaffey M, Grewal EP, Tazhibi M, Morshedy K, Aref AR, Batool SM, Guo X, Ijad N, Balaj L, Wakimoto H, Martinez-Lage M, Frigault MJ, Leick MB, Bernstock JD, Bi WL, Carter BS, Chiocca EA, Dietrich J, Gerstner ER, Boland GM, Nahed BV, Plotkin SR, Jenkins RW, Brastianos PK, Curry WT, Maus MV, Choi BD
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells. Neuro Oncol. 2025 Dec 01; 27(12):3104-3118.
Mesothelin is a surface antigen present on human meningioma and can be effectively targeted by CAR T-cells.
Urban T, Lim R, Merker VL, Muzikansky A, Harris GJ, Kassarjian A, Bredella MA, Plotkin SR
Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion. Clin Nucl Med. 2014 May; 39(5):e301-7.
Anatomic and metabolic evaluation of peripheral nerve sheath tumors in patients with neurofibromatosis 1 using whole-body MRI and (18)F-FDG PET fusion.
Chemoprevention for neurofibromatosis 2: just over the horizon? Neuro Oncol. 2014 Apr; 16(4):471-2.
Chemoprevention for neurofibromatosis 2: just over the horizon?
Widemann BC, Acosta MT, Ammoun S, Belzberg AJ, Bernards A, Blakeley J, Bretscher A, Cichowski K, Clapp DW, Dombi E, Evans GD, Ferner R, Fernandez-Valle C, Fisher MJ, Giovannini M, Gutmann DH, Hanemann CO, Hennigan R, Huson S, Ingram D, Kissil J, Korf BR, Legius E, Packer RJ, McClatchey AI, McCormick F, North K, Pehrsson M, Plotkin SR, Ramesh V, Ratner N, Schirmer S, Sherman L, Schorry E, Stevenson D, Stewart DR, Ullrich N, Bakker AC, Morrison H
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies. Am J Med Genet A. 2014 Mar; 164A(3):563-78.
CTF meeting 2012: Translation of the basic understanding of the biology and genetics of NF1, NF2, and schwannomatosis toward the development of effective therapies.
Merker VL, Bredella MA, Cai W, Kassarjian A, Harris GJ, Muzikansky A, Nguyen R, Mautner VF, Plotkin SR
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis. Am J Med Genet A. 2014 Jun; 164A(6):1431-7.
Relationship between whole-body tumor burden, clinical phenotype, and quality of life in patients with neurofibromatosis.
Jordan JT, Yang HS, Narendra D, Plotkin SR
Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis. Neurology. 2014 May 06; 82(18):e161-2.
Teaching NeuroImages: brain mass with hilar adenopathy: the importance of histologic diagnosis.
Youssef G, Aquilanti E, Miller JJ, Lan Z, Lasica AB, Arrillaga-Romany I, Batchelor TT, Berger TR, Beroukhim R, Chukwueke U, Dietrich J, Forst DA, Gerstner ER, Castro LNG, Jordan JT, Mcfaline-Figueroa JR, Lee EQ, Nayak L, Nakhate V, Ospina JP, Plotkin SR, Wang N, Rhee JY, Reardon DA, Wen PY
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma. Neuro Oncol. 2026 Mar 01; 28(3):752-764.
Prognostic significance of O6-methylguanine-DNA methyltransferase promoter methylation status in isocitrate dehydrogenase-mutant glioma.
Sengupta S, Benkers T, Blitstein M, Palmer E, Plotkin SR, Abramson JS
Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma. Clin Lymphoma Myeloma Leuk. 2014 Aug; 14(4):e111-3.
Posterior reversible encephalopathy syndrome (PRES) complicating newly-diagnosed diffuse large B-cell lymphoma.
Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. Cancer Chemother Pharmacol. 2014 Jun; 73(6):1197-204.
Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients.
Pier DB, Nunes FP, Plotkin SR, Stemmer-Rachamimov AO, Kim JC, Shih HA, Brastianos P, Lin AE
Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome. Eur J Med Genet. 2014 May-Jun; 57(6):269-74.
Turner syndrome and meningioma: support for a possible increased risk of neoplasia in Turner syndrome.
Ritvo E, Yuwiler A, Geller E, Plotkin S, Mason A, Saeger K
Maturational changes in blood serotonin levels and platelet counts. Biochem Med. 1971 Feb; 5(1):90-6.
Maturational changes in blood serotonin levels and platelet counts.
Boon AC, Plotkin S, Rimmelzwaan GF, Osterhaus AD
Viral vaccine meeting held in Barcelona, October 25-28, 2003. Vaccine. 2004 Mar 29; 22(11-12):1327-34.
Viral vaccine meeting held in Barcelona, October 25-28, 2003.
Ahlawat S, Debs P, Fayad LM, Plotkin SR, Widemann BC, Blakeley JO
Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab. J Neurooncol. 2025 Sep; 174(3):699-708.
Whole Body-MRI assessment of peripheral lesions in patients with NF2-related schwannomatosis on systemic bevacizumab.
Yin Z, Lu S, Wu L, Sun Y, Blake DC, Chen J, Landegger LD, Ho W, Xiu B, Jones AP, Muzikansky A, Shih HA, Stankovic KM, Plotkin SR, Xu L
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation. Theranostics. 2026; 16(8):4076-4089.
A cochlea-sparing strategy for non-invasive control of intracranial schwannomas via peripheral irradiation and anti-PD-1 therapy enhanced by STING activation.
Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, Oblinger JL, Blake DC, Landegger LD, Seist R, Ho W, Xiu B, Jones AP, Muzikansky A, Stankovic KM, Plotkin SR, Chang LS, Xu L
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model. bioRxiv. 2024 Dec 29.
Enhanced Tumor Control and Hearing Loss Prevention Achieved with Combined Immune Checkpoint Inhibitor and Anti-VEGF Therapy in Vestibular Schwannoma Model.
Haydu JE, Redd RA, Lei MM, Hochberg EP, Barnes JA, Armand P, Soumerai JD, Eichler AF, Jacobsen ED, Jordan JT, Jacobson CA, LaCasce AS, Arrillaga-Romany I, McFaline-Figueroa JR, Plotkin SR, Takvorian RW, Chukwueke UN, Crombie JL, Johnson PC, Karschnia P, Dietrich J, Nayak L, Abramson JS
A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma. Blood Adv. 2026 Jan 27; 10(2):479-491.
A retrospective study of treatment and outcomes in synchronous systemic and central nervous system large B-cell lymphoma.
History and clinical epidemiology of NF2-related schwannomatosis. Fam Cancer. 2025 Oct 29; 24(4):79.
History and clinical epidemiology of NF2-related schwannomatosis.
Advancements in Preclinical Models for NF2-Related Schwannomatosis Research. Cancers (Basel). 2026 Jan 11; 18(2).
Advancements in Preclinical Models for NF2-Related Schwannomatosis Research.
Carias SC, Buono FD, Von Imhof L, Yelamanchili SM, Chan H, Yohay KH, Nghiemphu PL, Babovic-Vuksanovic D, Plotkin SR, Merker VL
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectives. Fam Cancer. 2025 Dec 16; 25(1):4.
"It's not any one thing, it's always all of them, all at the same time": quality of life in NF2-related schwannomatosis from patient and clinician perspectives.
Wood CG, Kozanno L, Stemmer-Rachamimov A, Lee DJ, Barker FG, Carter BS, Plotkin SR, Jordan JT, Chang LS, Welling DB
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas. Laryngoscope. 2025 Nov; 135(11):4355-4363.
Increased Hemorrhage During Excision of Bevacizumab-Treated NF2-Related Vestibular Schwannomas.
Kaulen LD, Martinez-Lage M, Abramson JS, Karschnia P, Doubrovinskaia S, Shankar GM, Choi BD, Ramundo CM, Ehret F, Barnes JA, El-Jawahri A, Hochberg EP, Johnson PC, Soumerai JD, Plotkin SR, Batchelor TT, Wick W, Maus MV, Chen YB, Frigault MJ, Dietrich J
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy. Blood. 2025 Oct 16; 146(16):1902-1913.
Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell therapy.
Clinical epidemiology of NF2-related schwannomatosis. Handb Clin Neurol. 2025; 212:129-134.
Clinical epidemiology of NF2-related schwannomatosis.
Medical therapy for vestibular schwannoma. Handb Clin Neurol. 2025; 212:145-148.
Medical therapy for vestibular schwannoma.
Yin Z, Wu L, Zhang Y, Sun Y, Lee GY, Lu S, Gao X, Chen JW, Subudhi S, Ho W, Zhu C, Ren J, Ferraro GB, Muzikansky A, Stemmer-Rachamimov A, Mao J, Plotkin SR, Xu L
Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain. Adv Sci (Weinh). 2026 Feb 27; e15597.
Deciphering and Targeting the Schwannoma-Neuron-Macrophage Crosstalk for the Treatment of Schwannomatosis and Associated Pain.
Wood CG, Huey N, Carter C, Truong N, Ii Barker FG, Plotkin SR, Welling DB
Hearing preservation and restoration surgery in NF2-related schwannomatosis. Fam Cancer. 2026 Jan 31; 25(1):14.
Hearing preservation and restoration surgery in NF2-related schwannomatosis.
Lu S, Yin Z, Wu L, Sun Y, Chen J, Wu LMN, Oblinger JL, Blake DC, Xiu B, Landegger LD, Seist R, Ho W, Jones AP, Muzikansky A, Stankovic KM, Plotkin SR, Chang LS, Xu L
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss. Nat Commun. 2026 Feb 11; 17(1):1148.
NKG2D upregulation sensitizes tumors to combined anti-PD1 and anti-VEGF therapy and prevents hearing loss.
Fayad LM, Blakeley J, Plotkin S, Widemann B, Jacobs MA
Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis. ISRN Radiol. 2013; 2013:627932.
Whole Body MRI at 3T with Quantitative Diffusion Weighted Imaging and Contrast-Enhanced Sequences for the Characterization of Peripheral Lesions in Patients with Neurofibromatosis Type 2 and Schwannomatosis.
Magnetic resonance imaging observations in primary central nervous system lymphoma. JAMA Neurol. 2014 Jul 01; 71(7):918-9.
Magnetic resonance imaging observations in primary central nervous system lymphoma.
Vranceanu AM, Merker VL, Plotkin SR, Park ER
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study. J Neurooncol. 2014 Oct; 120(1):103-9.
The relaxation response resiliency program (3RP) in patients with neurofibromatosis 1, neurofibromatosis 2, and schwannomatosis: results from a pilot study.
Batchelor TT, Gerstner ER, Emblem KE, Duda DG, Kalpathy-Cramer J, Snuderl M, Ancukiewicz M, Polaskova P, Pinho MC, Jennings D, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Hochberg FH, Lu-Emerson C, Iafrate AJ, Ivy SP, Rosen B, Loeffler JS, Wen PY, Sorensen AG, Jain RK
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation. Neuro Oncol. 2014 Jul; 16 Suppl 3:iii12.
Increased perfusion due to vascular normalization improves oxygenation and survival in glioblastoma patients treated with cediranib with or without chemoradiation.
Plotkin SR, Albers AC, Babovic-Vuksanovic D, Blakeley JO, Breakefield XO, Dunn CM, Evans DG, Fisher MJ, Friedman JM, Giovannini M, Gutmann DH, Kalamarides M, McClatchey AI, Messiaen L, Morrison H, Parkinson DB, Stemmer-Rachamimov AO, Van Raamsdonk CD, Riccardi VM, Rosser T, Schindeler A, Smith MJ, Stevenson DA, Ullrich NJ, van der Vaart T, Weiss B, Widemann BC, Zhu Y, Bakker AC, Lloyd AC
Update from the 2013 International Neurofibromatosis Conference. Am J Med Genet A. 2014 Dec; 164A(12):2969-78.
Update from the 2013 International Neurofibromatosis Conference.
Kaley TJ, Wen P, Schiff D, Ligon K, Haidar S, Karimi S, Lassman AB, Nolan CP, DeAngelis LM, Gavrilovic I, Norden A, Drappatz J, Lee EQ, Purow B, Plotkin SR, Batchelor T, Abrey LE, Omuro A
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma. Neuro Oncol. 2015 Jan; 17(1):116-21.
Phase II trial of sunitinib for recurrent and progressive atypical and anaplastic meningioma.
Terry AR, Merker VL, Barker FG, Leffert L, Bateman BT, Souter I, Plotkin SR
Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system. Am J Obstet Gynecol. 2015 Jul; 213(1):108-109.
Pregnancy complications in women with rare tumor suppressor syndromes affecting central and peripheral nervous system.
Vranceanu AM, Merker VL, Park ER, Plotkin SR
Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature. J Neurooncol. 2015 Apr; 122(2):219-28.
Quality of life among children and adolescents with neurofibromatosis 1: a systematic review of the literature.
Park ER, Smith KB, Merker VL, Muzikansky A, Vranceanu AM, Wang DL, Plotkin SR
Examining perceived cancer risk among patients with neurofibromatosis type 1. J Neurooncol. 2015 Mar; 122(1):127-33.
Examining perceived cancer risk among patients with neurofibromatosis type 1.
Norden AD, Ligon KL, Hammond SN, Muzikansky A, Reardon DA, Kaley TJ, Batchelor TT, Plotkin SR, Raizer JJ, Wong ET, Drappatz J, Lesser GJ, Haidar S, Beroukhim R, Lee EQ, Doherty L, Lafrankie D, Gaffey SC, Gerard M, Smith KH, McCluskey C, Phuphanich S, Wen PY
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. Neurology. 2015 Jan 20; 84(3):280-6.
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma.
Jackman DM, Cioffredi LA, Jacobs L, Sharmeen F, Morse LK, Lucca J, Plotkin SR, Marcoux PJ, Rabin MS, Lynch TJ, Johnson BE, Kesari S
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer. Oncotarget. 2015 Feb 28; 6(6):4527-36.
A phase I trial of high dose gefitinib for patients with leptomeningeal metastases from non-small cell lung cancer.
Merker VL, Murphy TP, Hughes JB, Muzikansky A, Hughes MR, Souter I, Plotkin SR
Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1. Fertil Steril. 2015 Mar; 103(3):761-8.e1.
Outcomes of preimplantation genetic diagnosis in neurofibromatosis type 1.
Korf B, Ahmadian R, Allanson J, Aoki Y, Bakker A, Wright EB, Denger B, Elgersma Y, Gelb BD, Gripp KW, Kerr B, Kontaridis M, Lazaro C, Linardic C, Lozano R, MacRae CA, Messiaen L, Mulero-Navarro S, Neel B, Plotkin S, Rauen KA, Roberts A, Silva AJ, Sittampalam SG, Zhang C, Schoyer L
The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach. Am J Med Genet A. 2015 Aug; 167A(8):1741-6.
The third international meeting on genetic disorders in the RAS/MAPK pathway: towards a therapeutic approach.
Beauchamp RL, James MF, DeSouza PA, Wagh V, Zhao WN, Jordan JT, Stemmer-Rachamimov A, Plotkin SR, Gusella JF, Haggarty SJ, Ramesh V
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas. Oncotarget. 2015 Jul 10; 6(19):16981-97.
A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
Prakash K, Ranganathan PN, Mettus R, Reddy P, Srinivasan A, Plotkin S
Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration. J Virol. 1992 Jan; 66(1):167-71.
Generation of deletion mutants of simian immunodeficiency virus incapable of proviral integration.
Stivaros SM, Stemmer-Rachamimov AO, Alston R, Plotkin SR, Nadol JB, Quesnel A, O'Malley J, Whitfield GA, McCabe MG, Freeman SR, Lloyd SK, Wright NB, Kilday JP, Kamaly-Asl ID, Mills SJ, Rutherford SA, King AT, Evans DG
Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2. J Med Genet. 2015 Aug; 52(8):557-62.
Multiple synchronous sites of origin of vestibular schwannomas in neurofibromatosis Type 2.
Gao X, Zhao Y, Stemmer-Rachamimov AO, Liu H, Huang P, Chin S, Selig MK, Plotkin SR, Jain RK, Xu L
Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model. Proc Natl Acad Sci U S A. 2015 Nov 24; 112(47):14676-81.
Anti-VEGF treatment improves neurological function and augments radiation response in NF2 schwannoma model.
Jordan JT, Gerstner ER, Batchelor TT, Cahill DP, Plotkin SR
Glioblastoma care in the elderly. Cancer. 2016 Jan 15; 122(2):189-97.
Terry AR, Jordan JT, Schwamm L, Plotkin SR
Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach. Stroke. 2016 Jan; 47(1):60-5.
Increased Risk of Cerebrovascular Disease Among Patients With Neurofibromatosis Type 1: Population-Based Approach.
Naunheim MR, Plotkin SR, Franco RA, Song PC
Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery
Laryngeal Manifestations of Neurofibromatosis. Otolaryngol Head Neck Surg. 2016 Mar; 154(3):494-7.
Laryngeal Manifestations of Neurofibromatosis.
Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. Acta Neurol Scand. 2016 Jun; 133(6):475-80.
Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2.
Blakeley JO, Ye X, Duda DG, Halpin CF, Bergner AL, Muzikansky A, Merker VL, Gerstner ER, Fayad LM, Ahlawat S, Jacobs MA, Jain RK, Zalewski C, Dombi E, Widemann BC, Plotkin SR
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas. J Clin Oncol. 2016 05 10; 34(14):1669-75.
Efficacy and Biomarker Study of Bevacizumab for Hearing Loss Resulting From Neurofibromatosis Type 2-Associated Vestibular Schwannomas.
Merker VL, Bergner AL, Vranceanu AM, Muzikansky A, Slattery W, Plotkin SR
Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study. Otol Neurotol. 2016 06; 37(5):574-9.
Health-related Quality of Life of Individuals With Neurofibromatosis Type 2: Results From the NF2 Natural History Study.
Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis. Neuro Oncol. 2016 05; 18(5):624-38.
Therapeutic advances for the tumors associated with neurofibromatosis type 1, type 2, and schwannomatosis.
Stevenson DA, Schill L, Schoyer L, Andresen BS, Bakker A, Bayrak-Toydemir P, Burkitt-Wright E, Chatfield K, Elefteriou F, Elgersma Y, Fisher MJ, Franz D, Gelb BD, Goriely A, Gripp KW, Hardan AY, Keppler-Noreuil KM, Kerr B, Korf B, Leoni C, McCormick F, Plotkin SR, Rauen KA, Reilly K, Roberts A, Sandler A, Siegel D, Walsh K, Widemann BC
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway. Am J Med Genet A. 2016 08; 170(8):1959-66.
The Fourth International Symposium on Genetic Disorders of the Ras/MAPK pathway.
Hanemann CO, Blakeley JO, Nunes FP, Robertson K, Stemmer-Rachamimov A, Mautner V, Kurtz A, Ferguson M, Widemann BC, Evans DG, Ferner R, Carroll SL, Korf B, Wolkenstein P, Knight P, Plotkin SR
Current status and recommendations for biomarkers and biobanking in neurofibromatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S40-8.
Current status and recommendations for biomarkers and biobanking in neurofibromatosis.
Ahlawat S, Fayad LM, Khan MS, Bredella MA, Harris GJ, Evans DG, Farschtschi S, Jacobs MA, Chhabra A, Salamon JM, Wenzel R, Mautner VF, Dombi E, Cai W, Plotkin SR, Blakeley JO
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis. Neurology. 2016 Aug 16; 87(7 Suppl 1):S31-9.
Current whole-body MRI applications in the neurofibromatoses: NF1, NF2, and schwannomatosis.
Plotkin SR, Davis SD, Robertson KA, Akshintala S, Allen J, Fisher MJ, Blakeley JO, Widemann BC, Ferner RE, Marcus CL
Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1. Neurology. 2016 Aug 16; 87(7 Suppl 1):S13-20.
Sleep and pulmonary outcomes for clinical trials of airway plexiform neurofibromas in NF1.
Vranceanu AM, Riklin E, Merker VL, Macklin EA, Park ER, Plotkin SR
Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT. Neurology. 2016 Aug 23; 87(8):806-14.
Mind-body therapy via videoconferencing in patients with neurofibromatosis: An RCT.
Developing Endpoints to Facilitate Clinical Trials in Rare Diseases
Phase II trial of mTORC1/mTORC2 inhibitor AZD2014 for sporadic meningioma
Training Program in Nervous System Tumors
FETAL ALCOHOL EFFECTS ON BLOOD BRAIN BARRIER TRANSPORT
Children's Tumor Foundation 2016 Neurofibromatosis (NF) Conference
Ostrow KL, Bergner AL, Blakeley J, Evans DG, Ferner R, Friedman JM, Harris GJ, Jordan JT, Korf B, Langmead S, Leschziner G, Mautner V, Merker VL, Papi L, Plotkin SR, Slopis JM, Smith MJ, Stemmer-Rachamimov A, Yohay K, Belzberg AJ
Creation of an international registry to support discovery in schwannomatosis. Am J Med Genet A. 2017 Feb; 173(2):407-413.
Creation of an international registry to support discovery in schwannomatosis.
Batchelor T, Eichler AF, Plotkin SR, Drappatz J, Wen P, Sorensen AG, Gerstner E
Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma. J Clin Oncol. 2009 May 20; 27(15_suppl):2035.
Phase I trial of vatalanib (PTK787) in combination with standard radiation and temozolomide in patients with newly diagnosed glioblastoma.
Plotkin SR, Singh M, Cai W, O'Donnell C, Esparza S, Smith MJ, Harris GJ, Muzikansky A, Bredella MA, Kassarjian A
Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes. J Clin Oncol. 2009 May 20; 27(15_suppl):2074.
Whole-body MRI evaluation of tumor burden in the neurofibromatosis tumor suppressor syndromes.
Plotkin SR, Jennings D, Mouridsen K, Emblem KE, Sorensen AG
Vascular hemodynamic profiles of vestibular schwannomas and glioblastoma using MRI. J Clin Oncol. 2011 May 20; 29(15_suppl):2047.
Vascular hemodynamic profiles of vestibular schwannomas and glioblastoma using MRI.
Norden AD, Hammond S, Drappatz J, Phuphanich S, Reardon DA, Wong E, Plotkin SR, Lesser GJ, Raizer JJ, Batchelor T, Quant EC, Beroukhim R, Kaley TJ, Muzikansky A, Ciampa AS, Doherty LM, Smith KH, Gerard M, Sceppa C, Wen PY
Phase II study of monthly pasireotide LAR (SOM230C) for recurrent or progressive meningioma. J Clin Oncol. 2011 May 20; 29(15_suppl):2040.
Talaei-Khoei M, Riklin E, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis. J Neurooncol. 2017 01; 131(2):413-419.
First use of patient reported outcomes measurement information system (PROMIS) measures in adults with neurofibromatosis.
Whitley R, Arvin A, Prober C, Burchett S, Corey L, Powell D, Plotkin S, Starr S, Alford C, Connor J
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group. N Engl J Med. 1991 Feb 14; 324(7):444-9.
A controlled trial comparing vidarabine with acyclovir in neonatal herpes simplex virus infection. Infectious Diseases Collaborative Antiviral Study Group.
Primary nervous system lymphoma. Curr Treat Options Oncol. 2002 Dec; 3(6):525-35.
Neurologic complications of cancer therapy. Neurol Clin. 2003 Feb; 21(1):279-318, x.
Neurologic complications of cancer therapy.
Plotkin SR, Halpin CF, McKenna MJ, Batchelor TT, Loeffler JS, Barker FG
Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib. J Clin Oncol. 2008 May 20; 26(15_suppl):2045.
Treatment of progressive neurofibromatosis type 2-related vestibular schwannoma with erlotinib.
di Tomaso E, Frosch MP, Auluck PK, Cahill D, Duda DG, Plotkin SR, Loeffler JS, Sorensen AG, Batchelor TT, Jain RK
Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment. J Clin Oncol. 2008 May 20; 26(15_suppl):2009.
Characterization of blood vessels in brain autopsies of GBM patients who received antiangiogenic treatment.
Riklin E, Talaei-Khoei M, Merker VL, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM
First report of factors associated with satisfaction in patients with neurofibromatosis. Am J Med Genet A. 2017 03; 173(3):671-677.
First report of factors associated with satisfaction in patients with neurofibromatosis.
Ramsey AH, Steinmann WC, Capps A, Diaz A, Netland K, Plotkin S, Wuttke J
The Journal of the Louisiana State Medical Society : official organ of the Louisiana State Medical Society
St. Thomas Immunization Initiative. A student-run community action project. J La State Med Soc. 1997 Jun; 149(6):197-9.
St. Thomas Immunization Initiative. A student-run community action project.
Folk remedy use in the inner city. South Med J. 1999 Aug; 92(8):795-8.
Primary nervous-system lymphoma. Lancet Oncol. 2001 Jun; 2(6):354-65.
Advances in the therapy of primary central nervous system lymphoma. Clin Lymphoma. 2001 Mar; 1(4):263-75; discussion 276-7.
Advances in the therapy of primary central nervous system lymphoma.
Fabio P. Nunes, Scott R. Plotkin, Anat Stemmer-Rachamimov
Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach (Mehta, Chang, Vogelbaum, Guha, et al., Editors)
Histopathology and Molecular Pathogenesis of Schwannomas. Principles and Practices of Neuro-Oncology: A Multidisciplinary Approach (Mehta, Chang, Vogelbaum, Guha, et al., Editors). 2010; in press.
Histopathology and Molecular Pathogenesis of Schwannomas
Pappas Ctr for Neuro-Oncology, Yawkey 9E
Banks WA, Ortiz L, Plotkin SR, Kastin AJ
The Journal of pharmacology and experimental therapeutics
Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism. J Pharmacol Exp Ther. 1991 Dec; 259(3):988-96.
Human interleukin (IL) 1 alpha, murine IL-1 alpha and murine IL-1 beta are transported from blood to brain in the mouse by a shared saturable mechanism.
Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7.
Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme.
Cai W, Kassarjian A, Bredella MA, Harris GJ, Yoshida H, Mautner VF, Wenzel R, Plotkin SR
Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology. 2009 Mar; 250(3):665-73.
Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images.
Duhaime AC, Bonner K, McGowan KL, Schut L, Sutton LN, Plotkin S
Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery
Distribution of bacteria in the operating room environment and its relation to ventricular shunt infections: a prospective study. Childs Nerv Syst. 1991 Aug; 7(4):211-4.
Distribution of bacteria in the operating room environment and its relation to ventricular shunt infections: a prospective study.
MacCollin M, Chiocca EA, Evans DG, Friedman JM, Horvitz R, Jaramillo D, Lev M, Mautner VF, Niimura M, Plotkin SR, Sang CN, Stemmer-Rachamimov A, Roach ES
Diagnostic criteria for schwannomatosis. Neurology. 2005 Jun 14; 64(11):1838-45.
Diagnostic criteria for schwannomatosis.
Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain. J Neurooncol. 2008 Jan; 86(1):55-6.
Ramsay Hunt syndrome in a patient with metastatic lung cancer to brain.
James MF, Lelke JM, Maccollin M, Plotkin SR, Stemmer-Rachamimov AO, Ramesh V, Gusella JF
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth. Neurobiol Dis. 2008 Feb; 29(2):278-92.
Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
El-Jawahri A, Podgurski LM, Eichler AF, Plotkin SR, Temel JS, Mitchell SL, Chang Y, Barry MJ, Volandes AE
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial. J Clin Oncol. 2010 Jan 10; 28(2):305-10.
Use of video to facilitate end-of-life discussions with patients with cancer: a randomized controlled trial.
Plotkin SR, Stemmer-Rachamimov AO, Barker FG, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. N Engl J Med. 2009 Jul 23; 361(4):358-67.
Hearing improvement after bevacizumab in patients with neurofibromatosis type 2.
Gerstner ER, Eichler AF, Plotkin SR, Drappatz J, Doyle CL, Xu L, Duda DG, Wen PY, Jain RK, Batchelor TT
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide. J Neurooncol. 2011 Jun; 103(2):325-32.
Phase I trial with biomarker studies of vatalanib (PTK787) in patients with newly diagnosed glioblastoma treated with enzyme inducing anti-epileptic drugs and standard radiation and temozolomide.
Peripheral and cranial nerve sheath tumors. Curr Opin Neurol. 2005 Oct; 18(5):604-10.
Peripheral and cranial nerve sheath tumors.
Batchelor TT, Duda DG, di Tomaso E, Ancukiewicz M, Plotkin SR, Gerstner E, Eichler AF, Drappatz J, Hochberg FH, Benner T, Louis DN, Cohen KS, Chea H, Exarhopoulos A, Loeffler JS, Moses MA, Ivy P, Sorensen AG, Wen PY, Jain RK
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma. J Clin Oncol. 2010 Jun 10; 28(17):2817-23.
Phase II study of cediranib, an oral pan-vascular endothelial growth factor receptor tyrosine kinase inhibitor, in patients with recurrent glioblastoma.
Plotkin SR, Banks WA, Waguespack PJ, Kastin AJ
Ethanol alters the concentration of Met-enkephalin in brain by affecting peptide transport system-1 independent of preproenkephalin mRNA. J Neurosci Res. 1997 May 01; 48(3):273-80.
Ethanol alters the concentration of Met-enkephalin in brain by affecting peptide transport system-1 independent of preproenkephalin mRNA.
Plotkin SR, Bredella MA, Cai W, Kassarjian A, Harris GJ, Esparza S, Merker VL, Munn LL, Muzikansky A, Askenazi M, Nguyen R, Wenzel R, Mautner VF
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One. 2012; 7(4):e35711.
Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis.
Shen Y, Nunes F, Stemmer-Rachamimov A, James M, Mohapatra G, Plotkin S, Betensky RA, Engler DA, Roy J, Ramesh V, Gusella JF
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas. BMC Med Genomics. 2009 Jul 09; 2:42.
Genomic profiling distinguishes familial multiple and sporadic multiple meningiomas.
In Larry R. Squire, Editor-in-Chief, The New Encyclopedia of Neuroscience
Phakomatoses: Neurofibromatosis 2. In Larry R. Squire, Editor-in-Chief, The New Encyclopedia of Neuroscience. 2008.
Enhancing patient engagement in neurofibromatosis clinical trials
Vakharia KT, Henstrom D, Plotkin SR, Cheney M, Hadlock TA
Facial reanimation of patients with neurofibromatosis type 2. Neurosurgery. 2012 Jun; 70(2 Suppl Operative):237-43.
Facial reanimation of patients with neurofibromatosis type 2.
Zhang N, Chen J, Ferraro GB, Wu L, Datta M, Jain RK, Plotkin SR, Stemmer-Rachamimov A, Xu L
Anti-VEGF treatment improves neurological function in tumors of the nervous system. Exp Neurol. 2018 01; 299(Pt B):326-333.
Anti-VEGF treatment improves neurological function in tumors of the nervous system.
Plotkin SR, Banks WA, Cohn CS, Kastin AJ
Pharmacology, biochemistry, and behavior
Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance. Pharmacol Biochem Behav. 2001 Mar; 68(3):379-87.
Withdrawal from alcohol in withdrawal seizure-prone and -resistant mice: evidence for enkephalin resistance.
Traumatic cervical-spine disruption. N Engl J Med. 2001 10 11; 345(15):1134-5.
Update on primary central nervous system lymphoma. Curr Opin Neurol. 2005 Dec; 18(6):645-53.
Update on primary central nervous system lymphoma.
Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate. Clin Cancer Res. 2004 Sep 01; 10(17):5643-6.
Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.
Facial numbness in a man with inguinal and retroperitoneal masses. Nat Clin Pract Oncol. 2005 Jan; 2(1):54-8; quiz 1 p following 58.
Facial numbness in a man with inguinal and retroperitoneal masses.
Plotkin SR, Singh MA, O'Donnell CC, Harris GJ, McClatchey AI, Halpin C
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy. Nat Clin Pract Oncol. 2008 Aug; 5(8):487-91.
Audiologic and radiographic response of NF2-related vestibular schwannoma to erlotinib therapy.
Smith MJ, Boyd CD, MacCollin MM, Plotkin SR
Identity analysis of schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations. Clin Genet. 2009 May; 75(5):501-2.
Identity analysis of schwannomatosis kindreds with recurrent constitutional SMARCB1 (INI1) alterations.
Bredella MA, Torriani M, Hornicek F, Ouellette HA, Plamer WE, Williams Z, Fischman AJ, Plotkin SR
Value of PET in the assessment of patients with neurofibromatosis type 1. AJR Am J Roentgenol. 2007 Oct; 189(4):928-35.
Value of PET in the assessment of patients with neurofibromatosis type 1.
Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes. Neurol Clin. 2007 Nov; 25(4):925-46, viii.
Genetic causes of brain tumors: neurofibromatosis, tuberous sclerosis, von Hippel-Lindau, and other syndromes.
Wendell LC, Freeman SH, Plotkin SR, Sims JR
Clinical reasoning: a case of multiple intracerebral hemorrhages. Neurology. 2007 Dec 04; 69(23):E30-4.
Clinical reasoning: a case of multiple intracerebral hemorrhages.
Harris GJ, Plotkin SR, Maccollin M, Bhat S, Urban T, Lev MH, Slattery WH
Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II. Neurosurgery. 2008 Jun; 62(6):1314-9; discussion 1319-20.
Three-dimensional volumetrics for tracking vestibular schwannoma growth in neurofibromatosis type II.
Smith MJ, Esparza S, Merker VL, Muzikansky A, Bredella MA, Harris GJ, Kassarjian A, Cai W, Walker JA, Mautner VF, Plotkin SR
Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis. Clin Biochem. 2013 May; 46(7-8):698-700.
Plasma S100ß is not a useful biomarker for tumor burden in neurofibromatosis.
Cai W, Steinberg SM, Bredella MA, Basinsky G, Somarouthu B, Plotkin SR, Solomon J, Widemann BC, Harris GJ, Dombi E
Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods. Acad Radiol. 2018 02; 25(2):144-152.
Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1: Comparison of Two Methods.
Merker VL, McDannold S, Riklin E, Talaei-Khoei M, Sheridan MR, Jordan JT, Plotkin SR, Vranceanu AM
Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT. J Neurooncol. 2018 Jan; 136(2):335-342.
Health literacy assessment in adults with neurofibromatosis: electronic and short-form measurement using FCCHL and Health LiTT.
Otolaryngologic clinics of North America
Chemotherapy: present and future. Otolaryngol Clin North Am. 2012 Apr; 45(2):471-86, x.
Advances in experimental medicine and biology
Neurofibromatoses. Adv Exp Med Biol. 2012; 724:266-77.
Andronesi OC, Esmaeili M, Borra RJH, Emblem K, Gerstner ER, Pinho MC, Plotkin SR, Chi AS, Eichler AF, Dietrich J, Ivy SP, Wen PY, Duda DG, Jain R, Rosen BR, Sorensen GA, Batchelor TT
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival. NPJ Precis Oncol. 2017; 1.
Early changes in glioblastoma metabolism measured by MR spectroscopic imaging during combination of anti-angiogenic cediranib and chemoradiation therapy are associated with survival.
Jeyaretna DS, Curry WT, Batchelor TT, Stemmer-Rachamimov A, Plotkin SR
Exacerbation of cerebral radiation necrosis by bevacizumab. J Clin Oncol. 2011 Mar 01; 29(7):e159-62.
Exacerbation of cerebral radiation necrosis by bevacizumab.
Koczkowska M, Chen Y, Callens T, Gomes A, Sharp A, Johnson S, Hsiao MC, Chen Z, Balasubramanian M, Barnett CP, Becker TA, Ben-Shachar S, Bertola DR, Blakeley JO, Burkitt-Wright EMM, Callaway A, Crenshaw M, Cunha KS, Cunningham M, D'Agostino MD, Dahan K, De Luca A, Destrée A, Dhamija R, Eoli M, Evans DGR, Galvin-Parton P, George-Abraham JK, Gripp KW, Guevara-Campos J, Hanchard NA, Hernández-Chico C, Immken L, Janssens S, Jones KJ, Keena BA, Kochhar A, Liebelt J, Martir-Negron A, Mahoney MJ, Maystadt I, McDougall C, McEntagart M, Mendelsohn N, Miller DT, Mortier G, Morton J, Pappas J, Plotkin SR, Pond D, Rosenbaum K, Rubin K, Russell L, Rutledge LS, Saletti V, Schonberg R, Schreiber A, Seidel M, Siqveland E, Stockton DW, Trevisson E, Ullrich NJ, Upadhyaya M, van Minkelen R, Verhelst H, Wallace MR, Yap YS, Zackai E, Zonana J, Zurcher V, Claes K, Martin Y, Korf BR, Legius E, Messiaen LM
Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848. Am J Hum Genet. 2018 01 04; 102(1):69-87.
Genotype-Phenotype Correlation in NF1: Evidence for a More Severe Phenotype Associated with Missense Mutations Affecting NF1 Codons 844-848.
Plotkin SR, O'Donnell CC, Curry WT, Bove CM, MacCollin M, Nunes FP
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients. J Neurosurg Spine. 2011 Apr; 14(4):543-7.
Spinal ependymomas in neurofibromatosis Type 2: a retrospective analysis of 55 patients.
McQueen M, MacCollin M, Gusella J, Plotkin SR
The Journal of neuroscience nursing : journal of the American Association of Neuroscience Nurses
Patient and physician attitudes regarding clinical trials in neurofibromatosis 1. J Neurosci Nurs. 2008 Dec; 40(6):341-5.
Patient and physician attitudes regarding clinical trials in neurofibromatosis 1.
Plotkin SR, Merker VL, Halpin C, Jennings D, McKenna MJ, Harris GJ, Barker FG
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients. Otol Neurotol. 2012 Aug; 33(6):1046-52.
Bevacizumab for progressive vestibular schwannoma in neurofibromatosis type 2: a retrospective review of 31 patients.
Jordan JT, Smith MJ, Walker JA, Erdin S, Talkowski ME, Merker VL, Ramesh V, Cai W, Harris GJ, Bredella MA, Seijo M, Suuberg A, Gusella JF, Plotkin SR
Pain correlates with germline mutation in schwannomatosis. Medicine (Baltimore). 2018 Feb; 97(5):e9717.
Pain correlates with germline mutation in schwannomatosis.
Zhao Y, Liu P, Zhang N, Chen J, Landegger LD, Wu L, Zhao F, Zhao Y, Zhang Y, Zhang J, Fujita T, Stemmer-Rachamimov A, Ferraro GB, Liu H, Muzikansky A, Plotkin SR, Stankovic KM, Jain RK, Xu L
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models. Proc Natl Acad Sci U S A. 2018 02 27; 115(9):E2077-E2084.
Targeting the cMET pathway augments radiation response without adverse effect on hearing in NF2 schwannoma models.
The MGH Guide to Clinical Cancer Genetics (eds., DC Chung and DA Haber)
Neurofibromatosis and Schwannomatosis. The MGH Guide to Clinical Cancer Genetics (eds., DC Chung and DA Haber). 2010; in press.
Hagel C, Stemmer-Rachamimov AO, Bornemann A, Schuhmann M, Nagel C, Huson S, Evans DG, Plotkin S, Matthies C, Kluwe L, Mautner VF
Neuropathology : official journal of the Japanese Society of Neuropathology
Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas. Neuropathology. 2012 Dec; 32(6):611-6.
Clinical presentation, immunohistochemistry and electron microscopy indicate neurofibromatosis type 2-associated gliomas to be spinal ependymomas.
Regulation of met-enkephalin in animal models of alcoholism
Regulation of met-enkephalin in animal models of alcoholism. 1997.
Enkephalin, PPE mRNA, and PTS-1 in alcohol withdrawal seizure-prone and -resistant mice. Alcohol. 1998 Jan; 15(1):25-31.
Enkephalin, PPE mRNA, and PTS-1 in alcohol withdrawal seizure-prone and -resistant mice.
R Cavaliere, B O’Neill, S Plotkin, G van Imhoff, E Neuwelt, K Jahnke, L Abrey, T Batchelor, G Illerhaus, S Horning, G Petroni, B Lopes, and D Schiff
Primary CNS Post-Transplant Lymphoproliferative Disorder: The International PCNSL Collaborative Group Experience. Cancer. 2009; in press.
Primary CNS Post-Transplant Lymphoproliferative Disorder: The International PCNSL Collaborative Group Experience